QuartrQuartr

PTCT: Sephience’s global PKU launch drives strong adoption, with robust pipeline and disciplined growth

Less than 1 min read

Sephience’s global PKU launch shows rapid adoption and strong patient enthusiasm, driven by its unique clinical profile and support infrastructure. The company is expanding manufacturing, managing pricing, advancing R&D, and maintaining expense discipline. Regulatory engagement and partnerships support growth and future launches.

Based on PTC Therapeutics, Inc. [PTCT] Citi Annual Global Healthcare Conference 2025 Audio Transcript — Dec. 4 2025

Disclaimer